The RAS-Q® Technology

The RAS-Q® technology will offer a new therapeutic approach for patients suffering from pulmonary diseases. The device is based on conventional lung support technology, but also includes the lung’s flexible movement via a patented device-integrated compliance. This results in an extremely low flow resistance, allowing for lung support without the need for a blood pump. Therefore, mobilization of lung support patients will be possible for the first time.
The RAS-Q technology is under development and not approved for human use yet.

Compliance

Integrated compliance elements allow flexibility and movement inside the conventional stiff hollow fiber bundle

Low Resistance

Gold standard O2 and CO2 exchange at 80% lower pressure loss

Self-regulation

Recovery of physiological functions

Background

Background

Pulmonary disease is one of the leading causes of death worldwide. 9,5 million deaths during 2008 were caused by lung infections, lung cancer and chronic obstructive pulmonary diseases (COPD). Common reasons for lung diseases are smoking, air pollution as well as influenzas or genetics.
COPD is the most common chronic respiratory disease, also known as smoker lung. In the beginning stages of COPD, patients suffer from shortness of breath. End-stage COPD patients need invasive ventilation or tracheotomy, which highly restricts their quality of life, mobility and ability to communicate.

Partners and Sponsors

enmodes GmbH
enmodes GmbH
University Hospital Aachen
University Hospital Aachen
Clinic for Thoracic and Cardiovascular Surgery
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven
Cardiac Surgery
University Witten/Herdecke
University Witten/Herdecke
Pulmonary clinic Köln/Merheim
Medical University of Vienna
Medical University of Vienna
Division of Cardiac Surgery
This activity has received funding from the European Institute of Innovation and Technology (EIT)
This project has received funding from the Bundesministerium für Bildung und Forschung
This project has received funding from the Zentrales Innovatosprogramm Mittelstand (ZIM)
This project has received funding from the Zentrales Innovatosprogramm Mittelstand (ZIM)

RAS-Q® will be the world’s first long-term respiratory assist device providing robust, fully portable, cost-effective and protective treatment of pulmonary diseases.

News